BioArctic Announces Composition of Nomination Committee for 2027 Annual General Meeting

BioArctic AB has announced the formation of its Nomination Committee ahead of the company's 2027 Annual General Meeting.

Committee Composition and Shareholdings

The newly appointed Nomination Committee has been established in accordance with principles approved by the Annual General Meeting. It comprises representatives designated by the three largest shareholders based on voting rights as of September 30, 2026, alongside the Chair of the Board who acts as convener.

• Margareta Öhrvall, representing Demban AB
• Pär Gellerfors, representing Ackelsta AB
• Thomas Ehlin, serving as Chair of the Nomination Committee and representing Fjärde AP-fonden

As of September 30, 2026, these participating shareholders collectively held approximately 57 percent of the shares and 82 percent of the total votes in BioArctic AB.

Deadlines and Submission of Proposals

Shareholders wishing to submit proposals to the Nomination Committee must ensure their submissions are received by January 15, 2027. Proposals can be sent via email to designated contacts with the subject "Nomination Committee" or by mail to the company's Stockholm address.

The 2027 Annual General Meeting is scheduled to take place on Thursday, May 27, 2027, at 4:30 pm CEST in Stockholm. Any shareholder requesting to have a specific matter considered at the meeting must submit the request by April 15, 2027.

Verification and Company Background

Official instructions and further governance details remain accessible on BioArctic's corporate website. BioArctic AB is a Swedish research-based biopharmaceutical enterprise listed on Nasdaq Stockholm Large Cap, focusing on treatments for neurodegenerative disorders.